Drug Trial Radar · NCT01208090
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Oct 31, 2010
Primary completion
Oct 31, 2012
Study completion Nov 30, 2012
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Conditions
- Psoriasis
Interventions
ACT-128800Drug
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
PlaceboDrug
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with at least 75% improvement in PASI from baseline (PASI75) at Week 16.Time frame: Baseline to week 16
Locations
67 sites in 17 countries. Site status is shown where the registry gives one.
Clinical Investigative Site 1006
Feldkirch, Austria
Clinical Investigative Site 1002
Graz, Austria
Clinical Investigative Site 1004
Sankt Pölten, Austria
Clinical Investigative Site 1007
Vienna, Austria
Clinical Investigative Site 1001
Vienna, Austria
Clinical Investigative Site 1103
Brussels, Belgium
Clinical Investigative Site 1102
Edegem, Belgium
Clinical Investigative Site 1101
Liège, Belgium
Clinical Investigative Site 1205
Pleven, Bulgaria
Clinical Investigative Site 1204
Plovdiv, Bulgaria
Clinical Investigative Site 1202
Sofia, Bulgaria
Clinical Investigative Site 1201
Sofia, Bulgaria
Clinical Investigative Site 1203
Sofia, Bulgaria
Clinical Investigative Site 1206
Stara Zagora, Bulgaria
Clinical Investigative Site 1402
Hradec Králové, Czechia
Clinical Investigative Site 1405
Nový Jičín, Czechia
Clinical Investigative Site 1406
Pardubice, Czechia
Clinical Investigative Site 1401
Prague, Czechia
Clinical Investigative Site 1502
Copenhagen, Denmark
Clinical Investigative Site 1504
Roskilde, Denmark
Clinical Investigative Site 1704
Bordeaux, France
Clinical Investigative Site 1701
Nice, France
Clinical Investigative Site 1707
Paris, France
Clinical Investigative Site 1710
Paris, France
Clinical Investigative Site 1705
Pierre-Bénite, France
Clinical Investigative Site 1703
Poitiers, France
Clinical Investigative Site 1702
Saint-Etienne, France
Clinical Investigative Site 2002
Budapest, Hungary
Clinical Investigative Site 2001
Debrecen, Hungary
Clinical Investigative Site 2006
Miskolc, Hungary
Clinical Investigative Site 2005
Pécs, Hungary
Clinical Investigative Site 2003
Szeged, Hungary
Clinical Investigative Site 2004
Veszprém, Hungary
Clinical Investigative Site 2315
Ancona, Italy
Clinical Investigative Site 2303
Bergamo, Italy
Clinical Investigative Site 2307
Bologna, Italy
Clinical Investigative Site 2317
Genova, Italy
Clinical Investigative Site 2309
L’Aquila, Italy
Clinical Investigative Site 2310
Pisa, Italy
Clinical Investigative Site 2304
Roma, Italy
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.